136 related articles for article (PubMed ID: 34959641)
1. In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma.
Halatsch ME; Dwucet A; Schmidt CJ; Mühlnickel J; Heiland T; Zeiler K; Siegelin MD; Kast RE; Karpel-Massler G
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959641
[TBL] [Abstract][Full Text] [Related]
2. Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
[TBL] [Abstract][Full Text] [Related]
3. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Halatsch ME; Kast RE; Karpel-Massler G; Mayer B; Zolk O; Schmitz B; Scheuerle A; Maier L; Bullinger L; Mayer-Steinacker R; Schmidt C; Zeiler K; Elshaer Z; Panther P; Schmelzle B; Hallmen A; Dwucet A; Siegelin MD; Westhoff MA; Beckers K; Bouche G; Heiland T
Neurooncol Adv; 2021; 3(1):vdab075. PubMed ID: 34377985
[TBL] [Abstract][Full Text] [Related]
4. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Kast RE; Karpel-Massler G; Halatsch ME
Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
[TBL] [Abstract][Full Text] [Related]
6. MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.
Kast RE; Alfieri A; Assi HI; Burns TC; Elyamany AM; Gonzalez-Cao M; Karpel-Massler G; Marosi C; Salacz ME; Sardi I; Van Vlierberghe P; Zaghloul MS; Halatsch ME
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626167
[TBL] [Abstract][Full Text] [Related]
7. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME
Oncotarget; 2013 Apr; 4(4):502-30. PubMed ID: 23594434
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Karpel-Massler G; Kast RE; Westhoff MA; Dwucet A; Welscher N; Nonnenmacher L; Hlavac M; Siegelin MD; Wirtz CR; Debatin KM; Halatsch ME
J Neurooncol; 2015 Mar; 122(1):21-33. PubMed ID: 25524815
[TBL] [Abstract][Full Text] [Related]
9. Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Elinzano H; Toms S; Robison J; Mohler A; Carcieri A; Cielo D; Donnelly J; Disano D; Vatketich J; Baekey J; Sturtevant A; MacKinnon K; Wood R; Safran H
Am J Clin Oncol; 2021 Feb; 44(2):49-52. PubMed ID: 33284237
[TBL] [Abstract][Full Text] [Related]
10. Repurposing drugs for glioblastoma: From bench to bedside.
Basso J; Miranda A; Sousa J; Pais A; Vitorino C
Cancer Lett; 2018 Aug; 428():173-183. PubMed ID: 29729291
[TBL] [Abstract][Full Text] [Related]
11. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
12. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
13. Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma.
Senbabaoglu F; Aksu AC; Cingoz A; Seker-Polat F; Borklu-Yucel E; Solaroglu İ; Bagci-Onder T
Front Neurosci; 2020; 14():578316. PubMed ID: 33390879
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Omuro A; Chan TA; Abrey LE; Khasraw M; Reiner AS; Kaley TJ; Deangelis LM; Lassman AB; Nolan CP; Gavrilovic IT; Hormigo A; Salvant C; Heguy A; Kaufman A; Huse JT; Panageas KS; Hottinger AF; Mellinghoff I
Neuro Oncol; 2013 Feb; 15(2):242-50. PubMed ID: 23243055
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
[TBL] [Abstract][Full Text] [Related]
19. RIST: a potent new combination therapy for glioblastoma.
Nonnenmacher L; Westhoff MA; Fulda S; Karpel-Massler G; Halatsch ME; Engelke J; Simmet T; Corbacioglu S; Debatin KM
Int J Cancer; 2015 Feb; 136(4):E173-87. PubMed ID: 25123598
[TBL] [Abstract][Full Text] [Related]
20. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P
J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
